Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 study

医学 微小残留病 内科学 不利影响 耐火材料(行星科学) 临床终点 CD22 胃肠病学 临床研究阶段 急性淋巴细胞白血病 嵌合抗原受体 血液学 细胞因子释放综合征 CD20 肿瘤科 免疫学 临床试验 白血病 淋巴瘤 免疫疗法 癌症 生物 天体生物学 淋巴细胞白血病
作者
Jing Pan,Kaiting Tang,Yuechen Luo,Samuel Seery,Yue Tan,Biping Deng,Feng Liu,Xiuwen Xu,Zhuojun Ling,Weiliang Song,Jinlong Xu,Jiajia Duan,Zelin Wang,Chunyu Li,Kai Wang,Yi-Bing Zhang,Xinjian Yu,Qinlong Zheng,Liping Zhao,Jiecheng Zhang
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:24 (11): 1229-1241 被引量:75
标识
DOI:10.1016/s1470-2045(23)00436-9
摘要

Background Relapses frequently occur following CD19-directed chimeric antigen receptor (CAR) T-cell treatment for relapsed or refractory B-cell acute lymphocytic leukaemia in children. We aimed to assess the activity and safety of sequential CD19-directed and CD22-directed CAR T-cell treatments. Methods This single-centre, single-arm, phase 2 trial, done at Beijing GoBroad Boren Hospital, Beijing, China, included patients aged 1–18 years who had relapsed or refractory B-cell acute lymphocytic leukaemia with CD19 and CD22 positivity greater than 95% and an Eastern Cooperative Oncology Group performance status of 0–2. Patients were initially infused with CD19-directed CAR T cells intravenously, followed by CD22-directed CAR T-cell infusion after minimal residual disease-negative complete remission (or complete remission with incomplete haematological recovery) was reached and all adverse events (except haematological adverse events) were grade 2 or better. The target dose for each infusion was 0·5 × 106 to 5·0 × 106 cells per kg. The primary endpoint was objective response rate at 3 months after the first infusion. Secondary endpoints were duration of remission, event-free survival, disease-free survival, overall survival, safety, pharmacokinetics, and B-cell quantification. The prespecified activity analysis included patients who received the target dose and the safety analysis included all treated patients. This study is registered with ClinicalTrials.gov, NCT04340154, and enrolment has ended. Findings Between May 28, 2020, and Aug 16, 2022, 81 participants were enrolled, of whom 31 (38%) were female and 50 (62%) were male. Median age was 8 years (IQR 6–10), all patients were Asian. All 81 patients received the first infusion and 79 (98%) patients received sequential infusions, CD19-directed CAR T cells at a median dose of 2·7 × 106 per kg (IQR 1·1 × 106 to 3·7 × 106) and CD22-directed CAR T cells at a median dose of 2·2 × 106 per kg (1·1 × 106 to 3·7 × 106), with a median interval of 39 days (37–41) between the two infusions. 62 (77%) patients received the target dose, including two patients who did not receive CD22 CAR T cells. At 3 months, 60 (97%, 95% CI 89–100) of the 62 patients who received the target dose had an objective response. Median follow-up was 17·7 months (IQR 11·4–20·9). 18-month event-free survival for patients who received the target dose was 79% (95% CI 66–91), duration of remission was 80% (68–92), and disease-free survival was 80% (68–92) with transplantation censoring; overall survival was 96% (91–100). Common adverse events of grade 3 or 4 between CD19-directed CAR T-cell infusion and 30 days after CD22-directed CAR T-cell infusion included cytopenias (64 [79%] of 81 patients), cytokine release syndrome (15 [19%]), neurotoxicity (four [5%]), and infections (five [6%]). Non-haematological adverse events of grade 3 or worse more than 30 days after CD22-directed CAR T-cell infusion occurred in six (8%) of 79 patients. No treatment-related deaths occurred. CAR T-cell expansion was observed in all patients, with a median peak at 9 days (IQR 7–14) after CD19-directed and 12 days (10–15) after CD22-directed CAR T-cell infusion. At data cutoff, 35 (45%) of 77 evaluable patients had CAR transgenes and 59 (77%) had B-cell aplasia. Interpretation This sequential strategy induced deep and sustained responses with an acceptable toxicity profile, and thus potentially provides long-term benefits for children with this condition. Funding The National Key Research & Development Program of China, the CAMS Innovation Fund for Medical Sciences (CIFMS), and the Non-Profit Central Research Institute Fund of Chinese Academy of Medical Sciences. Translation For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
一个橡果发布了新的文献求助10
1秒前
自由土豆完成签到,获得积分10
1秒前
2秒前
wyc发布了新的文献求助10
3秒前
4秒前
FashionBoy的应助被开心快乐大王采纳,获得10
4秒前
4秒前
璐璇完成签到 ,获得积分10
6秒前
guofuyan完成签到 ,获得积分10
6秒前
6秒前
7秒前
molihuakai的应助被苗条梨愁采纳,获得10
7秒前
乐乐的应助被苗条梨愁采纳,获得10
7秒前
小蘑菇的应助被苗条梨愁采纳,获得10
7秒前
完美世界的应助被木染采纳,获得10
8秒前
汉堡包的应助被可恶地采纳,获得10
9秒前
9秒前
路人发布了新的文献求助10
9秒前
Jasper的应助被ZBH采纳,获得10
9秒前
CipherSage的应助被WTTPAXL采纳,获得10
9秒前
之予无为完成签到,获得积分10
10秒前
10秒前
水煮电吹风的应助被胡萝卜卜采纳,获得10
10秒前
我拿迪迦咋啦完成签到,获得积分10
10秒前
10秒前
小气杨桃完成签到,获得积分10
11秒前
Olivia完成签到,获得积分10
11秒前
清秀千兰发布了新的文献求助10
12秒前
Orange的应助被ZZKKZZ采纳,获得10
12秒前
12秒前
snail完成签到,获得积分10
12秒前
古娜拉完成签到,获得积分10
13秒前
之予无为发布了新的文献求助10
13秒前
大碗完成签到,获得积分10
13秒前
14秒前
Lucas的应助被路人采纳,获得10
17秒前
17秒前
烟花的应助被Dafu采纳,获得30
17秒前
18秒前
molihuakai的应助被尔尔采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183694
求助须知:如何正确求助?哪些是违规求助? 9572963
关于积分的说明 21828306
捐赠科研通 7780864
什么是DOI,文献DOI怎么找? 3434057
关于科研通互助平台的介绍 2558257
邀请新用户注册赠送积分活动 2480541